

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
08 June 2023 (08.06.2023)



(10) International Publication Number
WO 2023/100134 A1

(51) International Patent Classification:

A61K 31/4155 (2006.01) A61K 45/06 (2006.01)
A61K 31/506 (2006.01) A61P 35/00 (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2022/061652

(22) International Filing Date:

01 December 2022 (01.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/285,457 02 December 2021 (02.12.2021) US

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **ANDERS, Lars**; c/o Pfizer Inc., 10777 Science
Center Drive, San Diego, California 92121 (US). **LI, Jer-**
ry; c/o Pfizer Inc., 10777 Science Center Drive, San Diego,
California 92121 (US). **LIN, Tun Tun**; c/o Pfizer Inc.,
10777 Science Center Drive, San Diego, California 92121
(US). **VANARSDALE, Todd Lee**; c/o Pfizer Inc., 10777
Science Center Drive, San Diego, California 92121 (US).
WEI, Ping; c/o Pfizer Inc., 10777 Science Center Drive,
San Diego, California 92121 (US). **YANG, Jing**; c/o Pfizer
Inc., 10777 Science Center Drive, San Diego, California
92121 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route
206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack,
New Jersey 07977 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: METHODS AND DOSING REGIMENS COMPRISING A CDK2 INHIBITOR AND A CDK4 INHIBITOR FOR
TREATING CANCER

(57) Abstract: This disclosure relates to combination therapies for use in treating cancer, comprising a CDK2 inhibitor of Formula (I)
and a selective CDK4 inhibitor of Formula (II), each as further described herein, optionally in further combination with an additional
anti-cancer agent.

WO 2023/100134 A1